Opening stock page...
Fetching company snapshot, pricing, and intelligence.
AI confidence 70% · prior close shown (market closed)
BridgeBio Pharma, Inc. shows decelerating business momentum based on AlphaOS pipeline evidence, with mixed management execution.
Why it matters: Revenue +67% YoY in Q1 FY2026.
1 signal not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 1d ago
BBIO's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on BBIO.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for BridgeBio Pharma, Inc. (BBIO) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
AlphaOS industries
Investment snapshot
BBIO's AI investment thesis
Upgrade to Premium for BBIO's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$66.61
Market cap
$13.02B
Profitable
No
Revenue $194.50M
Net income
$-166.56M
FY Sep 1, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for BridgeBio Pharma, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow BridgeBio Pharma, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
The edge in healthcare no longer belongs to the biggest drug pipelines — it belongs to the most targeted ones.
Gene editing and mRNA platforms are moving from research curiosity to approved therapies faster than the market expected.
Breakthroughs in therapies, diagnostics, and digital health are transforming medical outcomes.